What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?

Chronic lymphocytic leukemia (CLL), with an incidence rate between 4 and 6 cases per 100,000 persons per year, is considered the most prevalent leukemia in the western world. Chemoimmunotherapy (such as fludarabine, cyclophosphamide, and rituximab), bendamustine plus rituximab, and, more recently, n...

Descripción completa

Detalles Bibliográficos
Autores principales: Bravaccini, Sara, Martinelli, Giovanni, Cerchione, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784498/
https://www.ncbi.nlm.nih.gov/pubmed/32907382
http://dx.doi.org/10.1177/0963689720950209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784498/
https://www.ncbi.nlm.nih.gov/pubmed/32907382
http://dx.doi.org/10.1177/0963689720950209

Ejemplares similares